Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 03, 2024 1:19pm
58 Views
Post# 35809034

RE:RE:Trials

RE:RE:TrialsI was thinking this week we would hear something but so far nothing.  We have been waiting for 2 1/2 months since the Arbitration ruling to hear anything regarding this company's future.
Painful lesson learned here regarding penny stocks : do not invest in penny stocks.  This is a classic example.  
My confusion is why would Andrew, Jamie and a few of the Directors loaded up on $.10 shares and $.20 warrants last year.  Was it all based on winning the Arbitration that was far from a sure thing or did they have some other plan in mind ?  Replicel lost the arbitration, surely there is some other backup plan which would possibly explain their substantial investments last year. 
I know that I personally was encouraged to put more money into the company knowing they were putting more skin in the game.  At this point that may have been a bad decision.

It is now time to hear where this company is going.
<< Previous
Bullboard Posts
Next >>